The global Vasomotor Symptoms Treatment market was valued at US$ 8810 million in 2023 and is anticipated to reach US$ 12400 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.

Vasomotor Symptoms Treatment Market

North American market for Vasomotor Symptoms Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Vasomotor Symptoms Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Vasomotor Symptoms Treatment include Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc. and Emcure Pharmaceuticals Limited, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Vasomotor Symptoms Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vasomotor Symptoms Treatment.

Report Scope

The Vasomotor Symptoms Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vasomotor Symptoms Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Vasomotor Symptoms Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Vasomotor Symptoms Treatment Market Report

Report Metric	Details
Report Name	Vasomotor Symptoms Treatment Market
Accounted market size in 2023	US$ 8810 million
Forecasted market size in 2030	US$ 12400 million
CAGR	5.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Hormonal Therapies Non-Hormonal Therapies Others
Segment by Application	Clinic Hospital Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vasomotor Symptoms Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vasomotor Symptoms Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Vasomotor Symptoms Treatment Market growing?

Ans: The Vasomotor Symptoms Treatment Market witnessing a CAGR of 5.0% during the forecast period 2024-2030.

What is the Vasomotor Symptoms Treatment Market size in 2030?

Ans: The Vasomotor Symptoms Treatment Market size in 2030 will be US$ 12400 million.

Who are the main players in the Vasomotor Symptoms Treatment Market report?

Ans: The main players in the Vasomotor Symptoms Treatment Market are Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

What are the Application segmentation covered in the Vasomotor Symptoms Treatment Market report?

Ans: The Applications covered in the Vasomotor Symptoms Treatment Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Vasomotor Symptoms Treatment Market report?

Ans: The Types covered in the Vasomotor Symptoms Treatment Market report are Hormonal Therapies, Non-Hormonal Therapies, Others

1 Vasomotor Symptoms Treatment Market Overview

1.1 Product Overview and Scope of Vasomotor Symptoms Treatment

1.2 Vasomotor Symptoms Treatment Segment by Type

1.2.1 Global Vasomotor Symptoms Treatment Market Value Comparison by Type (2024-2030)

1.2.2 Hormonal Therapies

1.2.3 Non-Hormonal Therapies

1.2.4 Others

1.3 Vasomotor Symptoms Treatment Segment by Application

1.3.1 Global Vasomotor Symptoms Treatment Market Value by Application: (2024-2030)

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Others

1.4 Global Vasomotor Symptoms Treatment Market Size Estimates and Forecasts

1.4.1 Global Vasomotor Symptoms Treatment Revenue 2019-2030

1.4.2 Global Vasomotor Symptoms Treatment Sales 2019-2030

1.4.3 Global Vasomotor Symptoms Treatment Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Vasomotor Symptoms Treatment Market Competition by Manufacturers

2.1 Global Vasomotor Symptoms Treatment Sales Market Share by Manufacturers (2019-2024)

2.2 Global Vasomotor Symptoms Treatment Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Vasomotor Symptoms Treatment Average Price by Manufacturers (2019-2024)

2.4 Global Vasomotor Symptoms Treatment Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Vasomotor Symptoms Treatment, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Vasomotor Symptoms Treatment, Product Type & Application

2.7 Vasomotor Symptoms Treatment Market Competitive Situation and Trends

2.7.1 Vasomotor Symptoms Treatment Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Vasomotor Symptoms Treatment Players Market Share by Revenue

2.7.3 Global Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Vasomotor Symptoms Treatment Retrospective Market Scenario by Region

3.1 Global Vasomotor Symptoms Treatment Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Vasomotor Symptoms Treatment Global Vasomotor Symptoms Treatment Sales by Region: 2019-2030

3.2.1 Global Vasomotor Symptoms Treatment Sales by Region: 2019-2024

3.2.2 Global Vasomotor Symptoms Treatment Sales by Region: 2025-2030

3.3 Global Vasomotor Symptoms Treatment Global Vasomotor Symptoms Treatment Revenue by Region: 2019-2030

3.3.1 Global Vasomotor Symptoms Treatment Revenue by Region: 2019-2024

3.3.2 Global Vasomotor Symptoms Treatment Revenue by Region: 2025-2030

3.4 North America Vasomotor Symptoms Treatment Market Facts & Figures by Country

3.4.1 North America Vasomotor Symptoms Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Vasomotor Symptoms Treatment Sales by Country (2019-2030)

3.4.3 North America Vasomotor Symptoms Treatment Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Vasomotor Symptoms Treatment Market Facts & Figures by Country

3.5.1 Europe Vasomotor Symptoms Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Vasomotor Symptoms Treatment Sales by Country (2019-2030)

3.5.3 Europe Vasomotor Symptoms Treatment Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Vasomotor Symptoms Treatment Market Facts & Figures by Country

3.6.1 Asia Pacific Vasomotor Symptoms Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Vasomotor Symptoms Treatment Sales by Country (2019-2030)

3.6.3 Asia Pacific Vasomotor Symptoms Treatment Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Vasomotor Symptoms Treatment Market Facts & Figures by Country

3.7.1 Latin America Vasomotor Symptoms Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Vasomotor Symptoms Treatment Sales by Country (2019-2030)

3.7.3 Latin America Vasomotor Symptoms Treatment Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Vasomotor Symptoms Treatment Market Facts & Figures by Country

3.8.1 Middle East and Africa Vasomotor Symptoms Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Vasomotor Symptoms Treatment Sales by Country (2019-2030)

3.8.3 Middle East and Africa Vasomotor Symptoms Treatment Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Vasomotor Symptoms Treatment Sales by Type (2019-2030)

4.1.1 Global Vasomotor Symptoms Treatment Sales by Type (2019-2024)

4.1.2 Global Vasomotor Symptoms Treatment Sales by Type (2025-2030)

4.1.3 Global Vasomotor Symptoms Treatment Sales Market Share by Type (2019-2030)

4.2 Global Vasomotor Symptoms Treatment Revenue by Type (2019-2030)

4.2.1 Global Vasomotor Symptoms Treatment Revenue by Type (2019-2024)

4.2.2 Global Vasomotor Symptoms Treatment Revenue by Type (2025-2030)

4.2.3 Global Vasomotor Symptoms Treatment Revenue Market Share by Type (2019-2030)

4.3 Global Vasomotor Symptoms Treatment Price by Type (2019-2030)

5 Segment by Application

5.1 Global Vasomotor Symptoms Treatment Sales by Application (2019-2030)

5.1.1 Global Vasomotor Symptoms Treatment Sales by Application (2019-2024)

5.1.2 Global Vasomotor Symptoms Treatment Sales by Application (2025-2030)

5.1.3 Global Vasomotor Symptoms Treatment Sales Market Share by Application (2019-2030)

5.2 Global Vasomotor Symptoms Treatment Revenue by Application (2019-2030)

5.2.1 Global Vasomotor Symptoms Treatment Revenue by Application (2019-2024)

5.2.2 Global Vasomotor Symptoms Treatment Revenue by Application (2025-2030)

5.2.3 Global Vasomotor Symptoms Treatment Revenue Market Share by Application (2019-2030)

5.3 Global Vasomotor Symptoms Treatment Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Bayer AG

6.1.1 Bayer AG Corporation Information

6.1.2 Bayer AG Description and Business Overview

6.1.3 Bayer AG Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Bayer AG Vasomotor Symptoms Treatment Product Portfolio

6.1.5 Bayer AG Recent Developments/Updates

6.2 Fervent Pharmaceuticals, LLC

6.2.1 Fervent Pharmaceuticals, LLC Corporation Information

6.2.2 Fervent Pharmaceuticals, LLC Description and Business Overview

6.2.3 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product Portfolio

6.2.5 Fervent Pharmaceuticals, LLC Recent Developments/Updates

6.3 Astellas Pharma Inc.

6.3.1 Astellas Pharma Inc. Corporation Information

6.3.2 Astellas Pharma Inc. Description and Business Overview

6.3.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Portfolio

6.3.5 Astellas Pharma Inc. Recent Developments/Updates

6.4 Frazier Healthcare Partners

6.4.1 Frazier Healthcare Partners Corporation Information

6.4.2 Frazier Healthcare Partners Description and Business Overview

6.4.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Portfolio

6.4.5 Frazier Healthcare Partners Recent Developments/Updates

6.5 Mitsubishi Tanabe Pharma Corporation

6.5.1 Mitsubishi Tanabe Pharma Corporation Corporation Information

6.5.2 Mitsubishi Tanabe Pharma Corporation Description and Business Overview

6.5.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product Portfolio

6.5.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates

6.6 Eli Lilly and Company

6.6.1 Eli Lilly and Company Corporation Information

6.6.2 Eli Lilly and Company Description and Business Overview

6.6.3 Eli Lilly and Company Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Eli Lilly and Company Vasomotor Symptoms Treatment Product Portfolio

6.6.5 Eli Lilly and Company Recent Developments/Updates

6.7 AbbVie Inc.

6.6.1 AbbVie Inc. Corporation Information

6.6.2 AbbVie Inc. Description and Business Overview

6.6.3 AbbVie Inc. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.4.4 AbbVie Inc. Vasomotor Symptoms Treatment Product Portfolio

6.7.5 AbbVie Inc. Recent Developments/Updates

6.8 AMAG Pharmaceuticals Inc.

6.8.1 AMAG Pharmaceuticals Inc. Corporation Information

6.8.2 AMAG Pharmaceuticals Inc. Description and Business Overview

6.8.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.8.4 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Portfolio

6.8.5 AMAG Pharmaceuticals Inc. Recent Developments/Updates

6.9 Emcure Pharmaceuticals Limited

6.9.1 Emcure Pharmaceuticals Limited Corporation Information

6.9.2 Emcure Pharmaceuticals Limited Description and Business Overview

6.9.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Portfolio

6.9.5 Emcure Pharmaceuticals Limited Recent Developments/Updates

6.10 Merck & Co., Inc.

6.10.1 Merck & Co., Inc. Corporation Information

6.10.2 Merck & Co., Inc. Description and Business Overview

6.10.3 Merck & Co., Inc. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Merck & Co., Inc. Vasomotor Symptoms Treatment Product Portfolio

6.10.5 Merck & Co., Inc. Recent Developments/Updates

6.11 Novartis AG

6.11.1 Novartis AG Corporation Information

6.11.2 Novartis AG Vasomotor Symptoms Treatment Description and Business Overview

6.11.3 Novartis AG Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Novartis AG Vasomotor Symptoms Treatment Product Portfolio

6.11.5 Novartis AG Recent Developments/Updates

6.12 Novo Nordisk A/S

6.12.1 Novo Nordisk A/S Corporation Information

6.12.2 Novo Nordisk A/S Vasomotor Symptoms Treatment Description and Business Overview

6.12.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Novo Nordisk A/S Vasomotor Symptoms Treatment Product Portfolio

6.12.5 Novo Nordisk A/S Recent Developments/Updates

6.13 Pfizer Inc.

6.13.1 Pfizer Inc. Corporation Information

6.13.2 Pfizer Inc. Vasomotor Symptoms Treatment Description and Business Overview

6.13.3 Pfizer Inc. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Pfizer Inc. Vasomotor Symptoms Treatment Product Portfolio

6.13.5 Pfizer Inc. Recent Developments/Updates

6.14 Teva Pharmaceutical Industries Ltd.

6.14.1 Teva Pharmaceutical Industries Ltd. Corporation Information

6.14.2 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Description and Business Overview

6.14.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Portfolio

6.14.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Vasomotor Symptoms Treatment Industry Chain Analysis

7.2 Vasomotor Symptoms Treatment Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Vasomotor Symptoms Treatment Production Mode & Process

7.4 Vasomotor Symptoms Treatment Sales and Marketing

7.4.1 Vasomotor Symptoms Treatment Sales Channels

7.4.2 Vasomotor Symptoms Treatment Distributors

7.5 Vasomotor Symptoms Treatment Customers

8 Vasomotor Symptoms Treatment Market Dynamics

8.1 Vasomotor Symptoms Treatment Industry Trends

8.2 Vasomotor Symptoms Treatment Market Drivers

8.3 Vasomotor Symptoms Treatment Market Challenges

8.4 Vasomotor Symptoms Treatment Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bayer

Astellas Pharma Inc

Eli Lilly and Company

AbbVie

Emcure Pharmaceuticals Limited

Teva Pharmaceutical Industries Ltd

Fervent Pharmaceuticals, LLC

List of Tables

Table 1. Global Vasomotor Symptoms Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Vasomotor Symptoms Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Vasomotor Symptoms Treatment Market Competitive Situation by Manufacturers in 2023

Table 4. Global Vasomotor Symptoms Treatment Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Vasomotor Symptoms Treatment Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Vasomotor Symptoms Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Vasomotor Symptoms Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Vasomotor Symptoms Treatment, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Vasomotor Symptoms Treatment, Product Type & Application

Table 12. Global Key Manufacturers of Vasomotor Symptoms Treatment, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Vasomotor Symptoms Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasomotor Symptoms Treatment as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Vasomotor Symptoms Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Vasomotor Symptoms Treatment Sales by Region (2019-2024) & (K Units)

Table 18. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2019-2024)

Table 19. Global Vasomotor Symptoms Treatment Sales by Region (2025-2030) & (K Units)

Table 20. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2025-2030)

Table 21. Global Vasomotor Symptoms Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Vasomotor Symptoms Treatment Revenue Market Share by Region (2019-2024)

Table 23. Global Vasomotor Symptoms Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Vasomotor Symptoms Treatment Revenue Market Share by Region (2025-2030)

Table 25. North America Vasomotor Symptoms Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)

Table 27. North America Vasomotor Symptoms Treatment Sales by Country (2025-2030) & (K Units)

Table 28. North America Vasomotor Symptoms Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Vasomotor Symptoms Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Vasomotor Symptoms Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)

Table 32. Europe Vasomotor Symptoms Treatment Sales by Country (2025-2030) & (K Units)

Table 33. Europe Vasomotor Symptoms Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Vasomotor Symptoms Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Vasomotor Symptoms Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Vasomotor Symptoms Treatment Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Vasomotor Symptoms Treatment Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Vasomotor Symptoms Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Vasomotor Symptoms Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Vasomotor Symptoms Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Vasomotor Symptoms Treatment Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Vasomotor Symptoms Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Vasomotor Symptoms Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Vasomotor Symptoms Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Vasomotor Symptoms Treatment Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Vasomotor Symptoms Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Vasomotor Symptoms Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Vasomotor Symptoms Treatment Sales (K Units) by Type (2019-2024)

Table 51. Global Vasomotor Symptoms Treatment Sales (K Units) by Type (2025-2030)

Table 52. Global Vasomotor Symptoms Treatment Sales Market Share by Type (2019-2024)

Table 53. Global Vasomotor Symptoms Treatment Sales Market Share by Type (2025-2030)

Table 54. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Vasomotor Symptoms Treatment Revenue Market Share by Type (2019-2024)

Table 57. Global Vasomotor Symptoms Treatment Revenue Market Share by Type (2025-2030)

Table 58. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Type (2019-2024)

Table 59. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Type (2025-2030)

Table 60. Global Vasomotor Symptoms Treatment Sales (K Units) by Application (2019-2024)

Table 61. Global Vasomotor Symptoms Treatment Sales (K Units) by Application (2025-2030)

Table 62. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2019-2024)

Table 63. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2025-2030)

Table 64. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Vasomotor Symptoms Treatment Revenue Market Share by Application (2019-2024)

Table 67. Global Vasomotor Symptoms Treatment Revenue Market Share by Application (2025-2030)

Table 68. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Application (2019-2024)

Table 69. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Application (2025-2030)

Table 70. Bayer AG Corporation Information

Table 71. Bayer AG Description and Business Overview

Table 72. Bayer AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Bayer AG Vasomotor Symptoms Treatment Product

Table 74. Bayer AG Recent Developments/Updates

Table 75. Fervent Pharmaceuticals, LLC Corporation Information

Table 76. Fervent Pharmaceuticals, LLC Description and Business Overview

Table 77. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product

Table 79. Fervent Pharmaceuticals, LLC Recent Developments/Updates

Table 80. Astellas Pharma Inc. Corporation Information

Table 81. Astellas Pharma Inc. Description and Business Overview

Table 82. Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Astellas Pharma Inc. Vasomotor Symptoms Treatment Product

Table 84. Astellas Pharma Inc. Recent Developments/Updates

Table 85. Frazier Healthcare Partners Corporation Information

Table 86. Frazier Healthcare Partners Description and Business Overview

Table 87. Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Frazier Healthcare Partners Vasomotor Symptoms Treatment Product

Table 89. Frazier Healthcare Partners Recent Developments/Updates

Table 90. Mitsubishi Tanabe Pharma Corporation Corporation Information

Table 91. Mitsubishi Tanabe Pharma Corporation Description and Business Overview

Table 92. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product

Table 94. Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates

Table 95. Eli Lilly and Company Corporation Information

Table 96. Eli Lilly and Company Description and Business Overview

Table 97. Eli Lilly and Company Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Eli Lilly and Company Vasomotor Symptoms Treatment Product

Table 99. Eli Lilly and Company Recent Developments/Updates

Table 100. AbbVie Inc. Corporation Information

Table 101. AbbVie Inc. Description and Business Overview

Table 102. AbbVie Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. AbbVie Inc. Vasomotor Symptoms Treatment Product

Table 104. AbbVie Inc. Recent Developments/Updates

Table 105. AMAG Pharmaceuticals Inc. Corporation Information

Table 106. AMAG Pharmaceuticals Inc. Description and Business Overview

Table 107. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product

Table 109. AMAG Pharmaceuticals Inc. Recent Developments/Updates

Table 110. Emcure Pharmaceuticals Limited Corporation Information

Table 111. Emcure Pharmaceuticals Limited Description and Business Overview

Table 112. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product

Table 114. Emcure Pharmaceuticals Limited Recent Developments/Updates

Table 115. Merck & Co., Inc. Corporation Information

Table 116. Merck & Co., Inc. Description and Business Overview

Table 117. Merck & Co., Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Merck & Co., Inc. Vasomotor Symptoms Treatment Product

Table 119. Merck & Co., Inc. Recent Developments/Updates

Table 120. Novartis AG Corporation Information

Table 121. Novartis AG Description and Business Overview

Table 122. Novartis AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Novartis AG Vasomotor Symptoms Treatment Product

Table 124. Novartis AG Recent Developments/Updates

Table 125. Novo Nordisk A/S Corporation Information

Table 126. Novo Nordisk A/S Description and Business Overview

Table 127. Novo Nordisk A/S Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Novo Nordisk A/S Vasomotor Symptoms Treatment Product

Table 129. Novo Nordisk A/S Recent Developments/Updates

Table 130. Pfizer Inc. Corporation Information

Table 131. Pfizer Inc. Description and Business Overview

Table 132. Pfizer Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Pfizer Inc. Vasomotor Symptoms Treatment Product

Table 134. Pfizer Inc. Recent Developments/Updates

Table 135. Teva Pharmaceutical Industries Ltd. Corporation Information

Table 136. Teva Pharmaceutical Industries Ltd. Description and Business Overview

Table 137. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product

Table 139. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Vasomotor Symptoms Treatment Distributors List

Table 143. Vasomotor Symptoms Treatment Customers List

Table 144. Vasomotor Symptoms Treatment Market Trends

Table 145. Vasomotor Symptoms Treatment Market Drivers

Table 146. Vasomotor Symptoms Treatment Market Challenges

Table 147. Vasomotor Symptoms Treatment Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Vasomotor Symptoms Treatment

Figure 2. Global Vasomotor Symptoms Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Vasomotor Symptoms Treatment Market Share by Type in 2023 & 2030

Figure 4. Hormonal Therapies Product Picture

Figure 5. Non-Hormonal Therapies Product Picture

Figure 6. Others Product Picture

Figure 7. Global Vasomotor Symptoms Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Vasomotor Symptoms Treatment Market Share by Application in 2023 & 2030

Figure 9. Clinic

Figure 10. Hospital

Figure 11. Others

Figure 12. Global Vasomotor Symptoms Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Vasomotor Symptoms Treatment Market Size (2019-2030) & (US$ Million)

Figure 14. Global Vasomotor Symptoms Treatment Sales (2019-2030) & (K Units)

Figure 15. Global Vasomotor Symptoms Treatment Average Price (US$/Unit) & (2019-2030)

Figure 16. Vasomotor Symptoms Treatment Report Years Considered

Figure 17. Vasomotor Symptoms Treatment Sales Share by Manufacturers in 2023

Figure 18. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Vasomotor Symptoms Treatment Players: Market Share by Revenue in 2023

Figure 20. Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Vasomotor Symptoms Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Vasomotor Symptoms Treatment Sales Market Share by Country (2019-2030)

Figure 23. North America Vasomotor Symptoms Treatment Revenue Market Share by Country (2019-2030)

Figure 24. United States Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Vasomotor Symptoms Treatment Sales Market Share by Country (2019-2030)

Figure 27. Europe Vasomotor Symptoms Treatment Revenue Market Share by Country (2019-2030)

Figure 28. Germany Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Vasomotor Symptoms Treatment Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Vasomotor Symptoms Treatment Revenue Market Share by Region (2019-2030)

Figure 35. China Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Vasomotor Symptoms Treatment Sales Market Share by Country (2019-2030)

Figure 43. Latin America Vasomotor Symptoms Treatment Revenue Market Share by Country (2019-2030)

Figure 44. Mexico Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Vasomotor Symptoms Treatment Sales Market Share by Country (2019-2030)

Figure 48. Middle East & Africa Vasomotor Symptoms Treatment Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Vasomotor Symptoms Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Vasomotor Symptoms Treatment by Type (2019-2030)

Figure 53. Global Revenue Market Share of Vasomotor Symptoms Treatment by Type (2019-2030)

Figure 54. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Vasomotor Symptoms Treatment by Application (2019-2030)

Figure 56. Global Revenue Market Share of Vasomotor Symptoms Treatment by Application (2019-2030)

Figure 57. Global Vasomotor Symptoms Treatment Price (US$/Unit) by Application (2019-2030)

Figure 58. Vasomotor Symptoms Treatment Value Chain

Figure 59. Vasomotor Symptoms Treatment Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Distributors Profiles

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions